Mineralys Therapeutics, Inc.
MLYS$2.25B
Mid CapNASDAQPharmaceutical Preparations🇺🇸North AmericaRADNOR51 employees
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Jul 15, 2026
17wMarket Overview
Stock performance and key metrics
MLYS News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
lorundrostat Dose 1
Hypertension
Lorundrostat
Obstructive Sleep Apnea
MLS-101 (Part I)
Hypertension, Renal
lorundrostat Dose 2
Hypertension
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
lorundrostat Dose 1 | Phase 3 | Hypertension | - | - |
Lorundrostat | Phase 3 | Obstructive Sleep Apnea | - | - |
MLS-101 (Part I) | Phase 2 | Hypertension, Renal | - | - |
lorundrostat Dose 2 | Phase 2 | Hypertension | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply